Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fortress Biotech, Inc.FBIO · Entity 6822 | Director | January 01, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fortress Biotech, Inc.
Report date January 01, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common stock, par value $0.001SEC Table I · non-derivative | Direct | 146,704 |
Reported balance
After 2026-01-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-01 · Grant · Acquired 27,322 · Balance 146,704 F1: The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person on the January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the issuer. F2: Total holdings include 143,365 shares underlying deferred restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person on the January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the issuer.
F2: Total holdings include 143,365 shares underlying deferred restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2026 Filed Jan 5, 2026 21:30 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | Grantcommon stock, par value $0.001 | 27,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001529687-26-000002 · form4-01052026_040117.xml · nonDerivative · entry 1 Harvey Jimmie · CIK 0001529687 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,704 F1 · shares: The Reporting Person was granted 27,322 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2027, 2028, and 2029, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person on the January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the issuer. F2 · balance_after: Total holdings include 143,365 shares underlying deferred restricted stock units. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:20 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | Grantcommon stock, par value $0.001 | 49,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000427 · form4-01032025_040105.xml · nonDerivative · entry 1 Harvey Jimmie · CIK 0001529687 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,382 F1 · shares: The Reporting Person was granted 49,383 shares of restricted stock pursuant to the Issuer's 2013 Stock Incentive Plan, as amended. One-third of the shares will vest on each of January 1, 2026, 2027, and 2028, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person on the January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the issuer. F2 · balance_after: Total holdings include 116,043 shares underlying deferred restricted stock units. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:49 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 6,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-000901 · tm241755-4_4seq1.xml · nonDerivative · entry 1 Harvey Jimmie · CIK 0001529687 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,999 F1 · shares: Effective October 10, 2023, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Split. F2 · shares: One-third of the shares will vest on each of January 1, 2025, 2026, and 2027, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the Reporting Person's termination of service, or earlier upon their death or change in control of the Issuer. F3 · balance_after: Total holdings include 66,660 shares underlying deferred restricted stock units. Read SEC document |
| January 01, 2023 Filed Jan 5, 2023 02:23 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-001094 · tm231728-1_4seq1.xml · nonDerivative · entry 1 Harvey Jimmie · CIK 0001529687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,000 F1 · shares: One-third of the shares will vest on each of January1, 2024, 2025 and 2026, subject to continued service. The Reporting Person elected to defer 100% of these restricted shares pursuant to the Issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the Reporting Person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the Issuer. F2 · balance_after: The total holdings include 900,000 shares of deferred restricted stock. Read SEC document |
| January 01, 2022 Filed Apr 29, 2022 20:19 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-053580 · tm2213913-4_4seq1.xml · nonDerivative · entry 1 Harvey Jimmie · CIK 0001529687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,000 F1 · shares: One-third of the shares will vest on each of January 1, 2023, 2024 and 2025, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer. F2 · balance_after: The total holdings include 800,000 shares of deferred restricted stock. Read SEC document |
| January 01, 2021 Filed Apr 9, 2021 21:21 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-048821 · tm219139d1_4.xml · nonDerivative · entry 1 Harvey Jimmie · CIK 0001529687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 F1 · shares: One-third of the shares will vest on each of January 1, 2022, 2023 and 2024, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer. F2 · balance_after: The total holdings include 700,000 shares of deferred restricted stock. Read SEC document |
| January 01, 2020 Filed Mar 13, 2020 20:06 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-033108 · tm2011481-1_form4.xml · nonDerivative · entry 1 Harvey Jimmie · CIK 0001529687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 F1 · shares: One-third of the shares will vest on each January 1, 2021, 2022 and 2023, subject to continued service. The reporting person elected to defer 80% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer. F2 · balance_after: The total holdings include 150,000 shares underlying deferred restricted stock units that were previously reported in Table II. Read SEC document |
| January 01, 2019 Filed Apr 12, 2019 20:08 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-019494 · tv516217_4.xml · nonDerivative · entry 1 Harvey Jimmie · CIK 0001529687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 F1 · shares: One-third of the shares will vest on each January 1, 2020, 2021 and 2022, subject to continued service. The reporting person elected to defer 100% of these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred shares will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or change in control of the issuer. F2 · balance_after: The total holdings include 150,000 shares underlying deferred restricted stock units that were previously reported in Table II. Read SEC document |
| January 01, 2018 Filed Nov 30, 2018 22:29 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-062680 · tv495937_4.xml · nonDerivative · entry 1 Harvey Jimmie · CIK 0001529687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 F1 · shares: One-third of the shares will vest on each of January 1, 2019, 2020, and 2021, subject to continued service. The reporting person elected to defer these restricted shares pursuant to the issuer's Deferred Compensation Plan for Directors and instead received deferred share units that are subject to the same vesting conditions. Vested deferred share units will be delivered to the reporting person in January of the year following the reporting person's termination of service, or earlier upon his death or a change in control. F2 · balance_after: The total holdings include 150,000 shares underlying deferred share units that were previously reported in Table II. Read SEC document |
| March 10, 2017 Filed Jul 21, 2017 20:08 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantDeferred Restricted Stock Units · Derivative | 16,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000719 · doc4_4608.xml · derivative · entry 3 Harvey Jimmie · CIK 0001529687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,998 Underlying: Common Stock · 16,666 shares Expires not disclosed F3 · derivative.exercise_price: The Reporting Person was granted RSUs for service on the Strategic Transaction Committee in 2015, vesting one-third annually beginning on March 12, 2016. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Plan. Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. F2 · price: Upon the vesting of RSUs, the Reporting Person deferred the receipt of 16,666 shares of common stock and received instead 16,666 shares of deferred RSUs. F3 · derivative.exercise_date: The Reporting Person was granted RSUs for service on the Strategic Transaction Committee in 2015, vesting one-third annually beginning on March 12, 2016. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Plan. Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. F3 · derivative.expiration_date: The Reporting Person was granted RSUs for service on the Strategic Transaction Committee in 2015, vesting one-third annually beginning on March 12, 2016. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Plan. Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. Read SEC document |
| March 10, 2017 Filed Jul 21, 2017 20:08 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantDeferred Restricted Stock Units · Derivative | 16,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000719 · doc4_4608.xml · derivative · entry 2 Harvey Jimmie · CIK 0001529687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,998 Underlying: Common Stock · 16,666 shares Expires not disclosed F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs") for service as a director in 2015, vesting one-third annually beginning on March 12, 2016. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. F2 · price: Upon the vesting of RSUs, the Reporting Person deferred the receipt of 16,666 shares of common stock and received instead 16,666 shares of deferred RSUs. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") for service as a director in 2015, vesting one-third annually beginning on March 12, 2016. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs") for service as a director in 2015, vesting one-third annually beginning on March 12, 2016. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. Read SEC document |
| January 01, 2017 Filed Jan 24, 2017 23:54 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantDeferred Restricted Stock Units · Derivative | 16,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000105 · doc4_4411.xml · derivative · entry 3 Harvey Jimmie · CIK 0001529687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,332 Underlying: Common Stock · 16,666 shares Expires not disclosed F3 · derivative.exercise_price: The Reporting Person was granted RSUs for service on the Strategic Transaction Committee in 2016, vesting one-third annually beginning on January 1, 2017. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Plan. Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. F2 · price: Upon the vesting of RSUs, the Reporting Person deferred the receipt of 16,666 shares of common stock and received instead 16,666 shares of deferred RSUs. F3 · derivative.exercise_date: The Reporting Person was granted RSUs for service on the Strategic Transaction Committee in 2016, vesting one-third annually beginning on January 1, 2017. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Plan. Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. F3 · derivative.expiration_date: The Reporting Person was granted RSUs for service on the Strategic Transaction Committee in 2016, vesting one-third annually beginning on January 1, 2017. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Plan. Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. Read SEC document |
| January 01, 2017 Filed Jan 24, 2017 23:54 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantDeferred Restricted Stock Units · Derivative | 16,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000105 · doc4_4411.xml · derivative · entry 2 Harvey Jimmie · CIK 0001529687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,332 Underlying: Common Stock · 16,666 shares Expires not disclosed F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs") for service as a director in 2016, vesting one-third annually beginning on January 1, 2017. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. F2 · price: Upon the vesting of RSUs, the Reporting Person deferred the receipt of 16,666 shares of common stock and received instead 16,666 shares of deferred RSUs. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") for service as a director in 2016, vesting one-third annually beginning on January 1, 2017. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs") for service as a director in 2016, vesting one-third annually beginning on January 1, 2017. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.